Charlotte's Web: How a Dying Girl Changed Cannabis Medicine Forever
The case for medical marijuana in epilepsy.
Bottom Line
A child with Dravet syndrome went from 50 seizures/day to 2-3/month on a CBD cannabis extract — a single case that catalyzed FDA drug approval and changed federal policy.
Why It Matters
This case became one of the most publicly visible examples of medical cannabis for pediatric epilepsy after being featured on CNN. It helped catalyze a wave of families seeking cannabis-based treatments for treatment-resistant epilepsy and contributed to legislative changes in multiple states. It also raised important questions about whole-plant extracts versus isolated compounds.
The Backstory
By the time Charlotte Figi was five years old, she had been through more medical interventions than most people experience in a lifetime. Born in October 2006, her first seizure came at three months — prolonged status epilepticus, the kind that can kill. An SCN1A gene mutation confirmed the diagnosis: Dravet syndrome, one of the most severe and treatment-resistant forms of childhood epilepsy.
She tried every approved medication. Benzodiazepines. Valproate. Levetiracetam. Topiramate. Clobazam. Phenobarbital. The ketogenic diet. None of them worked. By age five, she was having nearly 300 seizures a week — fifty convulsive episodes a day. She couldn't walk. She couldn't talk. She couldn't eat on her own. Her heart had stopped multiple times. Her parents were told she had "reached the end of the road."
Then her mother found a different road.
The Experiment No Doctor Would Prescribe
Paige Figi, Charlotte's mother, wasn't a scientist. She was a parent who had watched every medical option fail. Through exhaustive research — the desperate, middle-of-the-night kind that parents of dying children do — she learned about Cunha's 1980 CBD epilepsy trial and the scattered preclinical evidence that cannabidiol might reduce seizures.
In Colorado, medical marijuana was legal. Charlotte qualified under the state's compassionate use provisions. But no dispensary had what Paige needed: a product high in CBD and low in THC. THC was the point of most cannabis products. CBD was considered a byproduct.
The Stanley Brothers — Joel, Jesse, Jon, Jordan, Jared, and Josh — were Colorado cannabis growers who had been crossbreeding plants to produce a high-CBD, low-THC strain. They weren't doing it for any particular medical condition. They thought CBD-rich cannabis might help with inflammation and anxiety. When Paige Figi contacted them, they had a strain with roughly 17% CBD and less than 0.5% THC. Nobody had tried it on a child with epilepsy.
The Stanleys agreed to provide the extract for free. No contract. No formal protocol. Just a mother, a grower, and a neurologist named Edward Maa at Denver Health who was willing to monitor Charlotte's response. There was no IRB approval, no double-blind design, no control group. Just a child who was dying and an oil made from a plant that nobody thought of as medicine.
Charlotte received her first dose of what would later be named "Charlotte's Web" — a sublingual oil extracted from the Stanley Brothers' strain.
Her seizures stopped.
Not gradually. Not partially. Charlotte went from approximately 50 convulsive seizures per day to 2-3 nocturnal convulsions per month. The improvement appeared within weeks and persisted for over 20 months at the time of publication. During that time, she was weaned off all her other antiepileptic drugs. She started walking. She started talking. She started eating on her own.
50 → 2-3
convulsive seizures per day reduced to 2-3 per month — a >99% reduction in seizure frequency. Charlotte was subsequently weaned from all other antiepileptic medications.
For context, a 50% seizure reduction is considered a meaningful response in epilepsy treatment. Charlotte's response was orders of magnitude beyond what any drug trial has ever shown for Dravet syndrome.
Maa & Figi (2014), Epilepsia 55(6):783-6
The Case Report
Edward Maa, Chief of the Comprehensive Epilepsy Program at Denver Health, documented Charlotte's response in a 2014 case report published in Epilepsia, the field's flagship journal. The paper was co-authored by Paige Figi — the first time a parent had appeared as co-author on an academic case report about her own child's treatment with cannabis.
The paper was careful to note its limitations: this was a single case, uncontrolled, with no way to rule out natural disease fluctuation or placebo effects. But it also made a provocative argument: that whole-plant CBD extracts might work better than isolated pharmaceutical CBD, citing the potential for entourage effects from other cannabinoids and terpenes in the extract.
This argument — whole plant versus isolated compound — would become one of the most contentious debates in cannabis medicine. GW Pharmaceuticals was already developing purified CBD (Epidiolex) for FDA approval. The Maa and Figi paper implicitly questioned whether the pharmaceutical approach was the right one.
The CNN Effect
Charlotte's story had already reached the public before the academic paper. In August 2013, CNN Chief Medical Correspondent Sanjay Gupta aired a documentary called "Weed" that featured Charlotte prominently. Gupta — who had previously opposed medical marijuana — publicly reversed his position after investigating Charlotte's case and others like it.
“We have been terribly and systematically misled for nearly 70 years in the United States, and I apologize for my own role in that.”
— Sanjay Gupta, MD
CNN Chief Medical Correspondent
Publicly reversing his opposition to medical marijuana after investigating Charlotte Figi's case, August 2013
The documentary's impact was immediate and seismic. Families with epileptic children began moving to Colorado to access Charlotte's Web — a migration the media called "medical marijuana refugees." Colorado changed its laws to allow children to access CBD. Other states followed. The political momentum that would eventually lead to the 2018 Farm Bill (legalizing hemp-derived CBD nationally) traces directly to Charlotte's story.
The Scientific Legacy
Charlotte's case was never going to satisfy the standards of evidence-based medicine. A single case report with no control group is the lowest tier of clinical evidence. The scientific community was right to demand more.
But the case report did something no randomized trial could: it created the political and institutional will to run those trials. Orrin Devinsky's 2017 NEJM trial of CBD for Dravet syndrome — the gold-standard evidence that led to FDA approval — exists in a direct causal chain from Charlotte's story. GW Pharmaceuticals accelerated their Epidiolex program. The NIH expanded research funding. The DEA reclassified CBD.
The Whole Plant Debate
Maa and Figi's paper made a scientific claim that remains controversial: that "the desire to isolate and treat with pharmaceutical grade compounds from cannabis (specifically CBD) may be inferior to therapy with whole plant extracts."
The argument has intuitive appeal. Charlotte responded to a whole-plant extract containing not just CBD but trace amounts of THC, other minor cannabinoids, and terpenes. The entourage effect hypothesis suggests these compounds work synergistically. Some families report that their children respond to whole-plant extracts but not to purified CBD.
But the counterargument is equally strong. Pharmaceutical-grade CBD (Epidiolex) proved effective in large randomized trials. Standardized dosing, consistent purity, and quality control are essential for reliable medical treatment. Whole-plant extracts vary batch to batch in ways that make dosing uncertain and safety harder to guarantee.
This debate isn't resolved, and it may never be resolved cleanly. It's possible that both are right for different patients. What Charlotte's case demonstrated is that CBD — in some form — can profoundly reduce seizures in treatment-resistant epilepsy. The details of optimal delivery remain an active research question.
Charlotte
Charlotte Figi died on April 7, 2020, at the age of 13. The cause was complications likely related to COVID-19. She never used cannabis as a recreational drug. She was a child for whom a plant extract was the difference between hundreds of seizures a day and something approaching a normal life.
Her legacy is measurable: an FDA-approved drug, changed laws in dozens of states, expanded research funding, and a shift in how the medical establishment thinks about cannabis. She didn't choose to become a symbol. She was a little girl whose parents refused to let her die without trying everything.
Key Takeaways
Frequently Asked Questions
Cite this study
Maa, Edward; Figi, Paige. (2014). The case for medical marijuana in epilepsy.. Epilepsia, 55(6), 783-6. https://doi.org/10.1111/epi.12610